Funding news · Sep 22, 2026
BCI-Sonics Raises CNY 200M Seed Round Led by HSG
BCI-Sonics Raises CNY 200M Seed Round Led by HSG
BCI-Sonics, a Chinese brain-computer interface startup, has raised CNY 200,000,000 in a Seed round led by HSG (HongShan Capital/Sequoia China).
Who Raised
BCI-Sonics is building a non-invasive neural modulation platform based on low-intensity focused ultrasound. The technology is designed to reach deep brain regions with millimetre-level precision without surgery.
The company pairs its ultrasound technology with AI-driven closed-loop neural modulation, which is intended to read and adjust brain activity in real time. Its stated targets include conditions such as Parkinson's disease and chronic pain.
BCI-Sonics is working with universities and hospitals to validate clinical applications across both medical treatment and consumer health.
The Round
- Round type: Seed
- Amount raised: CNY 200,000,000
- Currency: CNY
- Funding date: September 22, 2026
- Funding stage (company): Seed
- Lead investor: HSG (HongShan Capital/Sequoia China)
Investors
The round drew a broad syndicate of investors:
- HSG (HongShan Capital/Sequoia China) — lead
- Yunqi Partners
- Proxima Ventures Ltd.
- Delian Capital
- Xuhui Science and Innovation Investment
- Yuanhe Holding (元禾控股)
- Jingwei Venture Partners
- Deshi Investment (德石投资)
What the Company Does
BCI-Sonics operates at the intersection of brain-computer interface technology, medical devices, and artificial intelligence. Its core approach rests on two pillars:
- Low-intensity focused ultrasound — a non-invasive method intended to reach deep brain regions with millimetre-level precision, avoiding the need for surgery
- AI-driven closed-loop neural modulation — a system designed to read and adjust brain activity in real time
The company's stated therapeutic targets include Parkinson's disease and chronic pain. Beyond medical treatment, it is also pursuing consumer health applications.
Validation Strategy
A distinguishing feature of BCI-Sonics' approach is its collaboration model. The company is working with universities and hospitals to validate clinical applications. This dual-track validation — academic and clinical — is a common pathway for neurotechnology companies seeking to establish both scientific credibility and eventual regulatory footing.
Why It Matters
Non-invasive deep-brain access is one of the harder problems in neurotechnology. Surgical implants can reach deep structures but carry procedural risk; non-invasive techniques have historically struggled with precision and depth. Focused ultrasound is one of the approaches being explored to bridge that gap.
If BCI-Sonics' platform can demonstrate millimetre-level precision at depth without surgery, it would address a meaningful constraint in the field. The closed-loop AI component adds a second layer: rather than one-way stimulation, the system is designed to read and respond to neural activity in real time.
The breadth of the investor syndicate — spanning multiple funds and strategic backers — suggests institutional interest in the company's technical direction at the Seed stage.
At a Glance
| Item | Detail |
|---|---|
| Company | BCI-Sonics |
| Sector | Brain-computer interface / Neurotechnology |
| Technology | Low-intensity focused ultrasound + AI closed-loop modulation |
| Round | Seed |
| Amount | CNY 200,000,000 |
| Date | September 22, 2026 |
| Lead Investor | HSG (HongShan Capital/Sequoia China) |
| Target Conditions | Parkinson's disease, chronic pain |
Outlook
With CNY 200 million in Seed funding and a syndicate led by HSG, BCI-Sonics is positioned to advance its non-invasive neural modulation platform. The company's progress will likely be measured by the clinical validation work it is conducting with universities and hospitals, and by how far its ultrasound-plus-AI approach can travel from research settings toward medical treatment and consumer health applications.